Skip to main content

Table 1 Direct treatment utilization and costs for the total cohort (n = 218)

From: The cost of antiretroviral therapy in Haiti

  Mean utilization per patient for the 1st year of ART Median utilization (IQ range) per patient for the 1st year of ART Mean cost per patient for the 1st year of ART ($US) Median cost (IQ range) per patient for the 1st year of ART ($US)
Pre-ART work-up (labor and laboratory studies) * * 58 61 (61 to 61)
Labor cost (# of ART visits) 12.6 14 (11 to 16) 51 51 (42 to 61)
CD4 cell counts** (# of tests) 1.1 1 (1 to 1) 32 30 (30 to 30)
ART monitoring labs (# of tests) 9.5 11 (6 to 12) 72 81 (46 to 92)
TB tests (# of tests) 1.7 0 (0 to 3) 8 0 (0 to 14)
Other laboratory tests (# of tests) 2.7 2 (1 to 3) 8 5 (0 to 13)
Chest radiographs (# of x-rays) 0.4 (0 to 1) 10 0 (0 to 24)
Anti-retroviral therapy (# of days on ART) 291 362 (241 to 375) 355 282 (225 to 583)
TB medications (# of days on therapy) 19 0 (0 to 0) 6 0 (0 to 0)
Other medications*** * * 33 28 (15 to 40)
Outside referrals 0.3 0 (0 to 0) 31 0 (0 to 0)
Hospitalizations 0.1 0 (0 to 0) 62 0 (0 to 0)
Telephone cards 2.4 2.4 (1 to 3) 3 3 (1 to 4)
Nutritional support * * 117 140 (0 to 180)
Total (# of days in care) 299 365 (357 to 365) 846 846 (654 to 1075)
  1. IQ range = interquartile range
  2. * No utilization units defined.
  3. ** This does not include the baseline CD4 cell count done before the initiation of ART; also, many patients had a 12-month CD4 cell count that was done more than 365 days after ART initiation, and was therefore excluded from the analysis.
  4. *** GHESKIO paid a mean cost of $US 33.69 per patient for other medications (i.e. not including ART or TB drugs). The mean cost per patient for medications purchased outside of GHESKIO was $US 4.31 (median cost of $US 1.23).